SCHEMBL8149332

SCHEMBL8149332

CCn1nc(O)ccc1=O

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.36
ALDH1A1 P00352 4/20 0.36
KDM4E B2RXH2 4/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HRH3 Q9Y5N1 2/20 0.35
LMNA P02545 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C19 P33261 1/20 0.34
TSHR P16473 1/20 0.34
POLB P06746 2/20 0.33
HPGD P15428 2/20 0.33
GAA P10253 1/20 0.33
PTGS2 P35354 1/20 0.33
RECQL P46063 1/20 0.33
ESR1 P03372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11248494 0.78 LMNA (0.43) MAPTALDH1A1KDM4EHTTHSD17B10
SCHEMBL10196841 0.77 GAA (0.40) MAPTALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL9362665 0.77 HRH3 (0.36) MAPTALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL21384024 0.76 MARS1 (0.43) MAPTALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL14872174 0.76 KDM4E (0.41) ALDH1A1KDM4EHTTHSD17B10CYP1A2
SCHEMBL12877231 0.75 TSHR (0.37) MAPTALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL17723466 0.75 PTGS2 (0.36) MAPTALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL6133704 0.75 ALDH1A1 (0.42) MAPTALDH1A1KDM4EHTTHSD17B10
SCHEMBL10194702 0.74 KDM4E (0.52) MAPTALDH1A1KDM4EHTTSMN1; SMN2
SCHEMBL24246974 0.73 HRH3 (0.37) MAPTALDH1A1KDM4EHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases ARRAY BIOPHARMA INC (US) 2022-02-15 US disclosed
WO-2019113190-A1 BICYCLIC FUSED PYRIDINE COMPOUNDS AS INHIBITORS OF TAM KINASES ARRAY BIOPHARMA INC. (US) 2019-06-13 WO disclosed
US-20100234352-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2010-09-16 US disclosed
US-20070185092-A1 FACTOR Xa INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2007-08-09 US disclosed
US-6071938-A FOR TREATMENT OF SMOOTH MUSCLE DISORDERS PFIZER INC. (US) 2000-06-06 US disclosed
US-5912244-A MUSCLE DISORDERS, BREATHING DISORDERS AND URINARY INCONTINENCE PFIZER INC. (US) 1999-06-15 US disclosed
EP-0712398-B1 BENZOPYRANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PFIZER LTD (GB) 1997-05-07 EP disclosed
CN-1128536-A Benzopyrans and pharmaceutical compositions containing them PFIZER LTD (GB) 1996-08-07 CN disclosed
EP-0712398-A1 BENZOPYRANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PFIZER LTD (GB) 1996-05-22 EP disclosed
WO-1995004730-A1 BENZOPYRANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM PFIZER LIMITED (GB) 1995-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185092-A1 FACTOR Xa INHIBITORS TFPI, F12, F11 MAPT 4564/4885ALDH1A1 1402/4885KDM4E 2399/4885
US-20100234352-A1 FACTOR XA INHIBITORS TFPI, F12, F11 MAPT 4564/4885ALDH1A1 1402/4885KDM4E 2399/4885
US-11247990-B1 Bicyclic fused pyridine compounds as inhibitors of TAM kinases MAP3K1, MAP3K3, MAP3K2 MAPT 1098/4885ALDH1A1 3807/4885KDM4E 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.